In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lineage Cell Therapeutics, Inc.

http://www.lineagecell.com

Latest From Lineage Cell Therapeutics, Inc.

Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally

10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.

China Approvals

Finance Watch: Merrimack And LianBio Are Latest To Liquidate As Options Run Out

Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.

Financing Restructuring

Bespoke Gene Therapy ‘Playbook’ Outlines Platform Approach To AAV-Based Treatments

Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.

Gene Therapy Clinical Trials

Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

Scrip Asks Artificial Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Medical Devices
    • Biomaterials
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Bioinformatics
  • Other Names / Subsidiaries
    • Asterias Biotherapeutics, Inc.
    • BioTime Acquisition Corp.
    • BioTime, Inc.
    • Cell Cure Neurosciences Ltd.
    • Embryome Sciences
    • ES Cell International Pte Ltd
    • LifeMap Sciences, Inc.
    • OncoCyte Corporation
    • ReCyte Therapeutics
UsernamePublicRestriction

Register